Halozyme Raises 2026 Financial Guidance and Announces Strategic Drug Delivery Acquisition
Summary
Halozyme Therapeutics provided strong preliminary 2025 revenue estimates and significantly raised its 2026 financial guidance, while also announcing the strategic acquisition of Surf Bio to expand its drug delivery technology portfolio.
Key Events
-
Strong Preliminary 2025 Revenue Estimates
The company estimates 2025 total revenue will be in the range of $1,385 million to $1,400 million, representing a year-over-year growth of 36% to 38%. Royalty revenue is estimated at $865 million to $870 million, with 51% to 52% year-over-year growth.
-
Significantly Raised 2026 Financial Guidance
Halozyme increased its 2026 total revenue guidance to $1,710 million - $1,810 million (from $1,430M - $1,530M), royalty revenue to $1,130 million - $1,170 million (from $900M - $940M), adjusted EBITDA to $1,125 million - $1,205 million (from $1,000M - $1,080M), and non-GAAP diluted EPS to $7.75 - $8.25 (from $6.50 - $7.00).
-
Strategic Acquisition of Surf Bio
Halozyme acquired Surf Bio in December 2025 for an upfront payment of $300 million and up to $100 million in milestone payments, totaling up to $400 million. This acquisition expands Halozyme's drug delivery portfolio with Surf Bio's hyperconcentration technology, which has long-duration intellectual property into the mid-2040s.
Analysis
Halozyme Therapeutics has significantly raised its financial guidance for 2026 across all key metrics, including total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. This substantial increase reflects strong momentum in its core ENHANZE business and robust demand for its drug delivery solutions. Additionally, the company announced the strategic acquisition of Surf Bio for up to $400 million, expanding its drug delivery portfolio with innovative hyperconcentration technology and extending its intellectual property horizons into the mid-2040s. These developments collectively reinforce Halozyme's long-term growth profile and commitment to delivering sustained shareholder value.
At the time of this filing, HALO was trading at $70.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3B. The 52-week trading range was $47.50 to $79.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.